The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...

Shares of Novavax Inc. NVAX slid 4.34% to $13.02 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.18% to 17,923.90 ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica is a writer on the Wellness team with a focus on health ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Sept. 11, 2024 – Social media platforms lit up minutes after the FDA announced its authorization of the updated Novavax COVID-19 vaccine right before Labor Day weekend. It was the last of three ...

Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. Recently, Zacks.com users have been paying close ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season. Jessica is a writer on the Wellness team with a focus on health ...

Novavax (NVAX) shares soared 19.2% in the last trading session to close at $14.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of ...

Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.